Amplify Cybersecurity ETF vs McKesson Corporation — how do they compare? Amplify Cybersecurity ETF trades at $123.68 (market cap $3.55B), while McKesson Corporation trades at $921.5 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 29.9× Amplify Cybersecurity ETF's market cap, and McKesson Corporation pays a 0.41% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 30 Days and McKesson Corporation for 74 Days on average.
| HACK | MCK | |
|---|---|---|
Market Cap | $3.55B | $106.14B |
Volume | 233,961 | 794,405 |
Sector | Sector/Thematic | Health |
52-Week High | $127.66 | $995.69 |
52-Week Low | $70.69 | $725.17 |
Typical Hold Time | 30 Days | 74 Days |
Enterprise Value | — | $112.67B |
Dividend Yield | — | 0.41% |
Signals from Pluang's Aura AI — not financial advice
HACK trades at $125.81, down 1.45% today but near its 52-week high, with a strong technical outlook showing bullish moving averages and key support at $124. Recent news highlights the ETF's momentum, driven by AI safety concerns and cybersecurity demand, with the fund up 84.96% from its 52-week low. Financial ratios are not disclosed for this ETF, but sector growth remains a tailwind.
The outlook for HACK is positive, supported by rising cybersecurity spending and AI-driven threats, though risks include increased short interest and sector volatility. Analyst sentiment is bullish, with the ETF positioned to benefit from ongoing digital security trends, but investors should monitor competitive and macroeconomic pressures.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →